HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AM Cosmetics

This article was originally published in The Rose Sheet

Executive Summary

Value-branded cosmetics firm seeking president and CEO after Arne Zimmerman announced intentions to step down at the end of the year. CFO Stephen Heit has been named acting president until the board finds permanent replacement. Both internal and external candidates will be considered for the position, which Zimmerman has held since joining AM Cosmetics in 1999 (1"The Rose Sheet" Feb. 15, 1999, p. 9). Zimmerman is credited with triggering a turnaround at AM Cosmetics. The company, which counts Wet n' Wild and Jonel among its brands, expects 2001 to be its most profitable year ever, Heit says. Zimmerman, also a CTFA board member, has left to pursue "new challenges"...

You may also be interested in...



AM Cosmetics' CEO Zimmerman Outlines Plan To Double Brand Sales

AM Cosmetics' newly appointed President and CEO Arnie Zimmerman is looking to double sales of each of the company's 10 value-priced brands within three years through expanded distribution and new introductions. Zimmerman recently succeeded Vince Wasik as the head of the firm.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

UsernamePublicRestriction

Register

RS009761

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel